Drug products: Propavan
ATC code: N05CM06
Substances: propiomazine, propiomazine maleate
No information on pharmacokinetic or pharmacodynamics differences between men and women has been found in the literature.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding pharmacokinetics or dosing of propiomazin have been found.
No studies with a clinically relevant sex analysis regarding dosing of propiomazin have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of propiomazin have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
In a Swedish registry study, all dispensed prescriptions to persons 75-89 years of age during a 4-month period in 2005 were analyzed. During this period, 105 007 women and 46 693 men were treated with hypnotics or sedatives. Of these, 16 289 women (16 %) and 8 961 men (19 %) were treated with propiomazine (adjusted odds ratio 0.77) . However, in 2012, the data of propiomazine utilization from The National Board of Health and Welfare show a higher dispensation to women . If this is a change over time or if it is due to the study focusing on shorter time period, while the drug utilization data was based on one year data, is not clear.
Date of litterature search: 2013-04-05
Reviewed by: Expertrådet för psykiatriska sjukdomar, Expertrådet för geriatriska sjukdomar
Approved by: Mia von Euler